677741-73-0Relevant academic research and scientific papers
The discovery of novel indole-2-carboxamides as cannabinoid CB1 receptor antagonists
Cowley, Phillip M.,Baker, James,Barn, David R.,Buchanan, Kirsteen I.,Carlyle, Ian,Clark, John K.,Clarkson, Thomas R.,Deehan, Maureen,Edwards, Darren,Goodwin, Richard R.,Jaap, David,Kiyoi, Yasuko,Mort, Chris,Palin, Ronald,Prosser, Alan,Walker, Glenn,Ward, Nick,Wishart, Grant,Young, Trevor
scheme or table, p. 497 - 501 (2011/02/24)
The discovery and structure-activity relationship of a novel series of indole-2-carboxamide antagonists of the cannabinoid CB1 receptor is disclosed. Compound 26i was found to be a high potency, selective cannabinoid CB1 antagonist.
N-Benzylindole-2-carboxylic acids: Potent functional antagonists of the CCR2b chemokine receptor
Kettle, Jason G.,Faull, Alan W.,Barker, Andy J.,Davies, D. Huw,Stone, Michael A.
, p. 405 - 408 (2007/10/03)
Screening of the corporate database led to the discovery of a novel series of N-benzylindole-2-carboxylic acid CCR2b chemokine receptor antagonists. These compounds demonstrate high affinity and functional inhibition of the CCR2b receptor. A discussion of
Indole derivatives as inhibitors or factor Xa
-
, (2010/11/29)
The present invention relates to the inhibition of blood clotting proteins, and more particularly, to indole derivatives of formula (I), in which R1a, R1b, R1cR1d, R2, R3, R4and A are defined as indicated in the claims. The compounds of formula (I) are inhibitors of the blood clotting enzyme factor Xa. The invention also relates to processes for the preparation of the compounds of formula (I), to methods of inhibiting factor Xa activity and of inhibiting blood clotting, to use of the compounds of formula (I) in the treatment and prophylaxis of diseases which can be cured or prevented by the inhibition of factor Xa activity such as thromboembolic diseases, and to the use of the compounds of formula (I) in the preparation of medicaments to be applied in such diseases. The invention further relates to compositions containing a compound of formula (I) in admixture or otherwise in association with an inert carrier, in particular pharmaceutical compositions containing a compound of formula (I) together with pharmaceutically acceptable carrier substances and/or auxiliary substances.
